DANIEL DULANEY: Open Payments
NPI 1538647417 · WEXFORD, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$772 in 40 payments from 11 companies in 2025. Trend: 2023 $129 · 2024 $157 · 2025 $772
Food & beverage: $772
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $351 |
| Otsuka America Pharmaceutical, Inc. | 5 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $16 |
Products named: VRAYLAR, REXULTI, CAPLYTA, TRINTELLIX, Qelbree, FANAPT, Auvelity, REJOYN.
Industry payments across PA — which companies pay providers there.
